Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

UK National Cancer Imaging Translational Accelerator (NCITA) establishes infrastructure for validation and adoption of cancer imaging biomarkers as decision-making tools in clinical trials and NHS practice. Researchers and medical experts from nine world-leading medical imaging centres across the UK come together to form an integrated infrastructure for standardising and validating cancer imaging biomarkers for clinical use.

None

The centres include University of Oxford, University College London, University of Manchester, King’s College London, The Institute of Cancer Research, London, and The Royal Marsden NHS Foundation Trust, Imperial College London, Cambridge University, Newcastle University and University of Glasgow.  This unique UK infrastructure provides clinical researchers across the UK with open access to world-class clinical imaging facilities and expertise, as well as a repository data management service, artificial intelligence (AI) tools and ongoing training opportunities.

The NCITA consortium, through engagement with NHS Trusts, pharmaceutical companies, medical imaging and nuclear medicine companies as well as funding bodies and patient groups, aims to develop a robust and sustainable imaging biomarker certification process, to revolutionise the speed and accuracy of cancer diagnosis, tumour classification and patient response to treatment. 

Read the full story on the Department of Oncology website